美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

美国抗疫概念

1,327.58

-9.1315-0.68%

涨家数：5

跌家数：15

平家数：- -

市盈率：- -

高：1,343.21

开：1,342.69

低：1,326.57

收：1,336.71

数据加载中...

总览新闻资讯

阿斯利康5月9日成交额为4.23亿美元

阿斯利康超 20 亿元投资的细胞治疗生产基地开业

Nanoviricides, Inc.盘中异动股价大跌5.67%

Aethlon Medical, Inc.盘中异动大幅下跌6.72%报0.344美元

Co-Diagnostics, Inc.盘中异动快速下挫5.69%报0.335美元

诺瓦瓦克斯医药盘中异动早盘股价大跌5.09%

Ocugen, Inc.盘中异动早盘股价大涨5.15%

Corvus Pharmaceuticals, Inc.股价拉升20.00% 市值涨5480.82万美元

江苏省委书记信长星会见阿斯利康全球执行副总裁、国际业务负责人尹思睿

江苏省委书记信长星会见阿斯利康全球执行副总裁、国际业务负责人尹思睿

阿斯利康PD-L1单抗一项III期研究成功

溃疡性结肠炎治疗添利器！强生古塞奇尤单抗在华再度获批新适应症

辉瑞5月8日成交额为12.75亿美元

莫德纳5月8日成交额为2.37亿美元

迪哲医药董事长张小林完成减持182.7万股套现1亿元用于个人资金需求

阿斯利康5月8日成交额为4.83亿美元

雅培5月8日成交额为8.05亿美元

诺瓦瓦克斯疫苗审批悬而未决，销售额却逆势猛增

生物制品圈

辉瑞新型抗菌药物获批儿童全年龄段适应症，耐药菌感染患儿福音

Corvus Pharmaceuticals, Inc.盘中异动股价大涨5.00%报3.36美元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK4568/news?region=SGP"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"美国抗疫概念","latestPrice":1327.5806,"timestamp":1746820799999,"preClose":1336.712,"halted":0,"volume":113582454,"delay":0,"changeRate":-0.006831,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-9.13147,"latestTime":"05-09 16:00:00 EDT","open":1342.69,"high":1343.2052,"low":1326.5701,"amount":4653162209.902576,"amplitude":0.012445,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.574095,"peRate":21.454016,"turnoverRate":0.007317,"increases":5,"decrements":15,"flats":0,"marketCap":1093969830401.5,"floatMarketCap":1075897192963},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1343.2052,"amplitude":0.012445,"preClose":1336.712,"low":1326.5701,"pbRate":"3.574095","latestPrice":1327.5806,"volume":113582454,"delay":0,"open":1342.69,"prevYearClose":1274.8187,"prevWeekClose":1375.2667,"prevMonthClose":1374.5028,"prevQuarterClose":1427.887,"fiveDayClose":1375.2667,"twentyDayClose":1281.7616,"sixtyDayClose":1380.7908,"secType":"PLATE","market":"US","turnoverRate":0.007317,"peRate":21.454016,"marketCap":1093969830401.5,"floatMarketCap":1075897192963,"timestamp":1746820799999,"nameCN":"美国抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":5,"down":15,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2534495247","title":"阿斯利康5月9日成交额为4.23亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2534495247","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534495247?lang=zh_cn&edition=fundamental","pubTime":"2025-05-10 09:17","pubTimestamp":1746839823,"startTime":"0","endTime":"0","summary":"美东时间2025年5月9日，阿斯利康成交额为4.23亿美元，成交额较昨日减少12.50%，当日成交量为621.60万股。阿斯利康于2025年5月9日涨0.4%，报67.57美元，该股过去5个交易日跌6.72%，年初至今涨4.81%，过去60日跌7.92%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-05-09|4.23亿|-12.50%|621.60万|#|2025-05-08|4.83亿|70.43%|714.59万|#|2025-05-07|2.83亿|-16.66%|404.00万|#|2025-05-06|3.40亿|54.27%|480.22万|#|2025-05-05|2.20亿|-43.09%|305.57万|1999 年，瑞典阿斯特拉公司与英国捷利康集团合并，成立了阿斯利康公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250510091710a478c66b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250510091710a478c66b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","BK4588","LU2417539215.USD","LU0109394709.USD","LU1829250122.USD","LU2456880835.USD","AZN","LU0889565916.HKD","LU2462157665.USD","LU2236285917.USD","BK4007","LU0320765992.SGD","BK4585"],"gpt_icon":0},{"id":"2534007493","title":"阿斯利康超 20 亿元投资的细胞治疗生产基地开业","url":"https://stock-news.laohu8.com/highlight/detail?id=2534007493","media":"医麦客","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534007493?lang=zh_cn&edition=fundamental","pubTime":"2025-05-10 07:21","pubTimestamp":1746832876,"startTime":"0","endTime":"0","summary":"2025 年 5 月 10 日医麦客新闻 eMedClub News近日，阿斯利康在美国马里兰州罗克维尔投资 3 亿美元新建的细胞治疗生产基正式开业。阿斯利康于去年 11 月首次宣布将在美国投资 35 亿美元用于研发和生产。与此同时，两个月前，阿斯利康又以 10 亿美元收购了比利时的 EsoBiotech 及其慢病毒载体平台，进军细胞治疗领域。阿斯利康表示，其最终目标是利用 FasTCAR 平台开发罕见疾病的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250510085931a478c26e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250510085931a478c26e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LU2456880835.USD","BK4568","LU2417539215.USD","LU0320765992.SGD","LU2462157665.USD","BK4585","LU2236285917.USD","LU0109394709.USD","LU1829250122.USD","AZN","BK4588","LU0889565916.HKD"],"gpt_icon":0},{"id":"2534455406","title":"Nanoviricides, Inc.盘中异动 股价大跌5.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2534455406","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534455406?lang=zh_cn&edition=fundamental","pubTime":"2025-05-10 00:28","pubTimestamp":1746808106,"startTime":"0","endTime":"0","summary":"北京时间2025年05月10日00时28分，Nanoviricides, Inc.股票出现波动，股价大幅下跌5.67%。Nanoviricides, Inc.股票所在的生物技术行业中，整体跌幅为2.94%。Nanoviricides, Inc.公司简介：Nanoviricides Inc是一家纳米生物制药公司，致力于发现、开发和商业化治疗剂，以推进对患有危及生命的病毒感染患者的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250510002826aa2c897e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250510002826aa2c897e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","BK4139","NNVC"],"gpt_icon":0},{"id":"2534436197","title":"Aethlon Medical, Inc.盘中异动 大幅下跌6.72%报0.344美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2534436197","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534436197?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 22:29","pubTimestamp":1746800972,"startTime":"0","endTime":"0","summary":"北京时间2025年05月09日22时29分，Aethlon Medical, Inc.股票出现异动，股价大幅跳水6.72%。截至发稿，该股报0.344美元/股，成交量1.3026万股，换手率0.08%，振幅7.83%。Aethlon Medical, Inc.股票所在的医疗器械行业中，整体涨幅为0.73%。其相关个股中，Envoy Medical Inc C/Wts 29/09/2028 、Ainos Inc C/Wts 29/07/2027 、Transmedics Group, Inc.涨幅较大，Invo Fertility, Inc.、Transmedics Group, Inc.、Accelerate Diagnostics, Inc.较为活跃，换手率分别为15.57%、7.54%、3.22%，振幅较大的相关个股有Tenon Medical Inc C/Wts 16/06/2028 、沃氪医疗、Rapid Micro Biosystems, Inc.，振幅分别为37.02%、25.64%、21.63%。Aethlon Medical, Inc.公司简介：Aethlon Medical Inc 是一家医疗技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050922293294f1e0ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050922293294f1e0ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AEMD","BK4082","BK4583","BK4568"],"gpt_icon":0},{"id":"2534081439","title":"Co-Diagnostics, Inc.盘中异动 快速下挫5.69%报0.335美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2534081439","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534081439?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 22:29","pubTimestamp":1746800963,"startTime":"0","endTime":"0","summary":"北京时间2025年05月09日22时29分，Co-Diagnostics, Inc.股票出现异动，股价急速跳水5.69%。截至发稿，该股报0.335美元/股，成交量1.7076万股，换手率0.05%，振幅5.57%。Co-Diagnostics, Inc.股票所在的医疗器械行业中，整体涨幅为0.73%。Co-Diagnostics, Inc.公司简介：Co-Diagnostics Inc是一家分子诊断公司。该公司还利用其专有技术为其 Co-Dx PCR 平台设计特定测试，并定位用于传染病以外应用的遗传标记。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509222923a4784962&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509222923a4784962&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4082","BK4568","CODX"],"gpt_icon":0},{"id":"2534554480","title":"诺瓦瓦克斯医药盘中异动 早盘股价大跌5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2534554480","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534554480?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 21:42","pubTimestamp":1746798149,"startTime":"0","endTime":"0","summary":"北京时间2025年05月09日21时42分，诺瓦瓦克斯医药股票出现异动，股价快速下跌5.09%。截至发稿，该股报6.32美元/股，成交量141.137万股，换手率0.87%，振幅4.73%。机构评级方面，在所有7家参与评级的机构中，57%的券商给予买入建议，29%的券商给予持有建议，14%的券商给予卖出建议。诺瓦瓦克斯医药股票所在的生物技术行业中，整体涨幅为0.46%。诺瓦瓦克斯医药公司简介：诺瓦瓦克斯医药公司是一家从事疫苗开发的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050921422994f1d761&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050921422994f1d761&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","NVAX","BK4588","BK4139","BK4568","BK4547"],"gpt_icon":0},{"id":"2534432816","title":"Ocugen, Inc.盘中异动 早盘股价大涨5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2534432816","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534432816?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 21:35","pubTimestamp":1746797747,"startTime":"0","endTime":"0","summary":"北京时间2025年05月09日21时35分，Ocugen, Inc.股票出现波动，股价急速上涨5.15%。Ocugen, Inc.股票所在的生物技术行业中，整体涨幅为0.63%。其相关个股中，Osr Holdings Inc C/Wts 09/02/2028 、Celularity Inc C/Wts 16/07/2026 、艾切托涨幅较大，Nucana Plc、Polyrizon Ltd.、Conduit Pharmaceuticals Inc.较为活跃，换手率分别为485.28%、117.92%、11.79%，振幅较大的相关个股有Celularity Inc C/Wts 16/07/2026 、Protalix Biotherapeutics, Inc. 、Vor Biopharma Inc.，振幅分别为76.90%、15.22%、13.63%。Ocugen, Inc.公司简介：Ocugen Inc 公司专注于发现、开发和商业化新型基因和细胞疗法和疫苗，以改善健康并为全球患者带来希望。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509213547a6d92db8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509213547a6d92db8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OCGN","BK4139","BK4568","BK4563"],"gpt_icon":0},{"id":"2534522435","title":"Corvus Pharmaceuticals, Inc.股价拉升20.00% 市值涨5480.82万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2534522435","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534522435?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 21:31","pubTimestamp":1746797465,"startTime":"0","endTime":"0","summary":"北京时间2025年05月09日21时31分，Corvus Pharmaceuticals, Inc.股票出现波动，股价快速上涨20.00%。Corvus Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.17%。其相关个股中，Osr Holdings Inc C/Wts 09/02/2028 、Corvus Pharmaceuticals, Inc.、艾切托涨幅较大，Nucana Plc、Polyrizon Ltd.、Conduit Pharmaceuticals Inc.较为活跃，换手率分别为424.20%、112.58%、10.46%，振幅较大的相关个股有Protalix Biotherapeutics, Inc. 、Prokidney Corp.、Assembly Biosciences, Inc.，振幅分别为15.22%、12.80%、11.08%。Corvus Pharmaceuticals, Inc.公司简介：Corvus Pharmaceuticals Inc 是一家临床阶段的生物制药公司，致力于开发针对免疫系统关键细胞元素的药物和抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509213105a4783c7d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509213105a4783c7d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CRVS","BK4568"],"gpt_icon":0},{"id":"2534484134","title":"江苏省委书记信长星会见阿斯利康全球执行副总裁、国际业务负责人尹思睿","url":"https://stock-news.laohu8.com/highlight/detail?id=2534484134","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534484134?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 21:03","pubTimestamp":1746795780,"startTime":"0","endTime":"0","summary":"5月9日，江苏省委书记信长星在南京会见阿斯利康全球执行副总裁、国际业务负责人尹思睿。信长星说，生物医药是江苏重点打造的战略性新兴产业，有着良好产业基础和广阔市场空间。阿斯利康是全球领先的生物制药企业，投资江苏30多年来取得丰硕成果。希望阿斯利康继续深耕江苏，进一步加大研发和投资布局，提供更多高质量的医疗健康产品和服务。我们将持续营造一流营商环境，为企业发展提供优质服务保障。尹思睿介绍了阿斯利康在江苏业务进展和未来发展计划。她表示，中国市场对阿斯利康十分重要，我们对与江苏的深化合作充满信心，将以此次新工厂开工建设为契机，不断拓展在苏业务布局，推动更多优质项目落地见效。（“微讯江苏”微信公号）","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509210405a6d925b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509210405a6d925b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","BK4588","LU2417539215.USD","LU0109394709.USD","LU1829250122.USD","LU2456880835.USD","AZN","LU0889565916.HKD","LU2462157665.USD","LU2236285917.USD","BK4007","LU0320765992.SGD","BK4585"],"gpt_icon":0},{"id":"2534484615","title":"江苏省委书记信长星会见阿斯利康全球执行副总裁、国际业务负责人尹思睿","url":"https://stock-news.laohu8.com/highlight/detail?id=2534484615","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534484615?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 21:01","pubTimestamp":1746795661,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["AZN","LU2456880835.USD","LU0109394709.USD","159760","BK4588","LU0320765992.SGD","LU1829250122.USD","BK4614","LU2236285917.USD","LU2417539215.USD","BK4568","LU2462157665.USD","LU0889565916.HKD","BK4585","BK4007","YINN"],"gpt_icon":0},{"id":"2534120879","title":"阿斯利康PD-L1单抗一项III期研究成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2534120879","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534120879?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 15:39","pubTimestamp":1746776382,"startTime":"0","endTime":"0","summary":"5月9日，阿斯利康宣布Imfinzi联合标准治疗治疗高危非肌层浸润性膀胱癌患者的III期POTOMAC研究取得了积极的高水平结果。结果显示，治疗一年后，与BCG组相比，度伐利尤单抗+BCG组患者的无疾病生存期显著延长且具有临床意义。膀胱癌是世界上第九大最常见的癌症，全球每年有超过61.4万例新诊断病例。目前NMIBC的SOC是TURBT术后+BCG。高达80%的患者在5年内出现疾病复发，高危患者的疾病进展率可高达45%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509155609a6d8c3f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509155609a6d8c3f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["III","LU2236285917.USD","BK4585","LU0889565916.HKD","LU0109394709.USD","BK4568","LU1169590202.USD","PD","BK4007","LU2456880835.USD","LU1829250122.USD","BK4134","BK4023","LU1169589451.USD","LU2417539215.USD","BK4588","LU2462157665.USD","AZN","LU0320765992.SGD"],"gpt_icon":0},{"id":"2534145044","title":"溃疡性结肠炎治疗添利器！强生古塞奇尤单抗在华再度获批新适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2534145044","media":"上观新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534145044?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 12:05","pubTimestamp":1746763553,"startTime":"0","endTime":"0","summary":"强生公司今天宣布，特诺雅达（古塞奇尤单抗注射液－静脉输注）和特诺雅（古塞奇尤单抗注射液）在华获批用于治疗对传统治疗或生物制剂应答不充分、失应答或不耐受的中度至重度活动性溃疡性结肠炎成人患者。今年2月，古塞奇尤单抗在华获得了其全球首个针对克罗恩病的批准，此次获批标志着它成为中国首个用于治疗溃疡性结肠炎的白介素-23抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505093400492063.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1718418525.SGD","LU1032466523.USD","LU1929549753.HKD","LU1261432733.SGD","LU0122379950.USD","LU1894683348.USD","LU2347655156.SGD","LU2592432038.USD","LU2505996681.GBP","BK4581","IE00B19Z3581.USD","BK4550","BK4592","LU1196500208.SGD","LU0466842654.USD","LU0345769631.USD","LU2602419157.SGD","LU0058720904.USD","LU1057294990.SGD","IE00B3T34201.USD","IE00BLSP4452.SGD","LU2129689605.HKD","LU0345770308.USD","LU0098860793.USD","IE000M9KFDE8.USD","LU1674673428.USD","IE00B2B36J28.USD","LU1935042991.SGD","LU2468319806.SGD","IE00BVYPNV92.GBP","LU0345769128.USD","IE0009355771.USD","BK4532","IE00BDGV0183.EUR","LU1894683264.USD","SG9999001440.SGD","BK4568","LU1066051225.USD","IE00B42XCP33.USD","IE00BBT3K403.USD","LU0912757837.SGD","LU1023059063.AUD","LU1074936037.SGD","LU1267930813.SGD","IE00BSNM7G36.USD","LU1430594728.SGD","BK4504","JNJ","IE00B3PB1722.GBP","LU0882574055.USD"],"gpt_icon":0},{"id":"2534596114","title":"辉瑞5月8日成交额为12.75亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2534596114","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534596114?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 10:29","pubTimestamp":1746757760,"startTime":"0","endTime":"0","summary":"美东时间2025年5月8日，辉瑞成交额为12.75亿美元，成交额较昨日增加15.30%，当日成交量为5566.98万股。辉瑞于2025年5月8日涨0.79%，报22.97美元，该股过去5个交易日跌4.01%，年初至今跌11.98%，过去60日跌10.03%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-05-08|12.75亿|15.30%|5566.98万|#|2025-05-07|11.06亿|-21.84%|4836.99万|#|2025-05-06|14.15亿|44.73%|6087.26万|#|2025-05-05|9.78亿|-2.97%|4081.18万|#|2025-05-02|10.08亿|-10.53%|4168.58万|辉瑞是全球最大的制药公司之一，年销售额接近500亿美元。辉瑞在全球销售这些产品，国际销售额占其总销售额的近50%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509102925a4778295&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509102925a4778295&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SGXZ57979304.SGD","IE00BLSP4239.USD","LU0289739699.SGD","IE00B19Z3581.USD","BK4533","BK4599","LU0868494617.USD","LU1066051498.USD","LU0456855351.SGD","IE00B19Z3B42.SGD","LU1894683264.USD","LU0321505868.SGD","LU1894683348.USD","LU0225284248.USD","LU1883839398.USD","SG9999002232.USD","BK4550","IE0002270589.USD","LU0058720904.USD","PFE","LU1057294990.SGD","LU0122379950.USD","IE00BBT3K403.USD","SG9999001176.USD","BK4585","BK4568","IE000M9KFDE8.USD","SG9999003800.SGD","SG9999011175.SGD","IE00BLSP4452.SGD","SG9999002224.SGD","SG9999013999.USD","LU0985481810.HKD","LU0170899867.USD","LU1066053197.SGD","SG9999001176.SGD","LU0321505439.SGD","LU0234572021.USD","BK4592","LU1023059063.AUD","BK4581","LU0306806265.USD","LU0225771236.USD","BK4588","BK4534","BK4007","LU0306807586.USD"],"gpt_icon":1},{"id":"2534192231","title":"莫德纳5月8日成交额为2.37亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2534192231","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534192231?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 10:11","pubTimestamp":1746756682,"startTime":"0","endTime":"0","summary":"美东时间2025年5月8日，莫德纳成交额为2.37亿美元，成交额较昨日减少9.19%，当日成交量为968.03万股。莫德纳于2025年5月8日涨1.33%，报24.38美元，该股过去5个交易日跌9.8%，年初至今跌41.37%，过去60日跌21.18%。截至 2024年9月，莫德纳拥有处于临床试验中的40个mRNA开发候选物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509101125a4777ddd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509101125a4777ddd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4534","BK4548","MRNA","BK4501","BK4585","BK4139","BK4568","BK4588","BK4533","BK4532","BK4551"],"gpt_icon":1},{"id":"2534119716","title":"迪哲医药董事长张小林完成减持182.7万股 套现1亿元用于个人资金需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2534119716","media":"DoNews","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534119716?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 09:40","pubTimestamp":1746754802,"startTime":"0","endTime":"0","summary":"5月8日，迪哲医药披露董事兼高管减持结果公告。公司董事长兼首席执行官张小林通过集中竞价方式累计减持182.7万股，占公司总股本0.4%，减持总金额达1亿元。本次减持计划于2025年4月3日至5月7日实施完毕，减持资金将用于偿还借款等个人用途。减持前，张小林直接持有公司731.1万股，其中部分股份来源于股权激励及二级市场增持。迪哲医药2024年营收同比增长294%至3.6亿元，净亏损收窄至8.46亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505090957199753e4ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505090957199753e4ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","BK4007","LU1829250122.USD","LU2417539215.USD","LU2456880835.USD","BK4568","LU0889565916.HKD","LU2236285917.USD","AZN","LU2462157665.USD","LU0320765992.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"2534118844","title":"阿斯利康5月8日成交额为4.83亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2534118844","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534118844?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 09:16","pubTimestamp":1746753419,"startTime":"0","endTime":"0","summary":"美东时间2025年5月8日，阿斯利康成交额为4.83亿美元，成交额较昨日增加70.43%，当日成交量为714.59万股。阿斯利康于2025年5月8日跌3.95%，报67.3美元，该股过去5个交易日跌4.55%，年初至今涨4.39%，过去60日跌6.11%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-05-08|4.83亿|70.43%|714.59万|#|2025-05-07|2.83亿|-16.66%|404.00万|#|2025-05-06|3.40亿|54.27%|480.22万|#|2025-05-05|2.20亿|-43.09%|305.57万|#|2025-05-02|3.87亿|-5.31%|537.45万|1999 年，瑞典阿斯特拉公司与英国捷利康集团合并，成立了阿斯利康公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509091705a4776d6f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509091705a4776d6f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2236285917.USD","LU2417539215.USD","LU1829250122.USD","BK4585","LU0889565916.HKD","BK4568","AZN","LU2456880835.USD","LU0109394709.USD","BK4588","BK4007","LU2462157665.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2534190009","title":"雅培5月8日成交额为8.05亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2534190009","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534190009?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 09:15","pubTimestamp":1746753319,"startTime":"0","endTime":"0","summary":"美东时间2025年5月8日，雅培成交额为8.05亿美元，成交额较昨日增加22.21%，当日成交量为599.45万股。雅培于2025年5月8日涨0.04%，报134.0美元，该股过去5个交易日涨2.38%，年初至今涨19.64%，过去60日涨2.42%。雅培约 60% 的销售额来自美国以外地区。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509091534a6d85fb0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509091534a6d85fb0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0266013472.USD","BK4566","LU1691799644.USD","LU1989763690.USD","LU0170899867.USD","LU1721429741.USD","SG9999002232.USD","LU1914381329.SGD","SG9999002224.SGD","LU1057294990.SGD","BK4588","LU1023059063.AUD","IE0009355771.USD","BK4082","BK4581","LU2237957902.USD","IE0002141913.USD","IE00BJT1NW94.SGD","BK4504","SGXZ23171101.USD","LU1721429402.USD","LU0122379950.USD","LU1061106388.HKD","LU2133065610.SGD","BK4533","BK4568","IE00BFTCPJ56.SGD","LU0234572021.USD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU2468319806.SGD","BK4592","BK4585","IE00BJJMRZ35.SGD","ABT","LU2237957811.SGD","LU2089984988.USD","SG9999004303.SGD","LU0868494617.USD","LU1989763427.SGD","LU2112291526.USD"],"gpt_icon":0},{"id":"2534118303","title":"诺瓦瓦克斯疫苗审批悬而未决，销售额却逆势猛增","url":"https://stock-news.laohu8.com/highlight/detail?id=2534118303","media":"生物制品圈","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534118303?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 08:36","pubTimestamp":1746750967,"startTime":"0","endTime":"0","summary":"近日，该公司在第一季度财报中披露的销售数据引发热议，尽管其新冠疫苗在美国食品药品监督管理局的审批仍前途未卜，但销售额却实现了大幅增长。此外，诺瓦瓦克斯还对其疫苗的优势进行宣传。受这些积极因素影响，诺瓦瓦克斯将 2025 年全年收入预期从 9.75 亿美元上调至 10.3 亿美元 。诺瓦瓦克斯在疫苗审批和市场销售上呈现出的这种矛盾态势，凸显了疫苗行业面临的复杂局面。整个行业都在密切关注，期待诺瓦瓦克斯能给出答案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509092611a4776f7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509092611a4776f7b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4009","BK4588","HHS","BK4585","BK4568","BK4139","NVAX","BK4547"],"gpt_icon":0},{"id":"2534962195","title":"辉瑞新型抗菌药物获批儿童全年龄段适应症，耐药菌感染患儿福音","url":"https://stock-news.laohu8.com/highlight/detail?id=2534962195","media":"药事纵横","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534962195?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 06:02","pubTimestamp":1746741739,"startTime":"0","endTime":"0","summary":"此次获批意味着思福妥在中国的适用人群从成人拓展到了全年龄段儿童，包括新生儿。中国儿童耐药菌感染的形势较为严峻。CRE感染的患儿，其30天死亡风险比敏感菌感染者高出近6倍。AMR已经被世界卫生组织列为十大公共卫生威胁之一，而儿童由于免疫系统尚未发育成熟，更容易受到耐药菌的侵袭。总的来说，思福妥儿童全年龄段适应症的获批是抗感染治疗领域的重大突破。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509063142a47745a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509063142a47745a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999001176.USD","LU0868494617.USD","LU0985481810.HKD","LU0234572021.USD","IE00BLSP4239.USD","BK4592","SG9999011175.SGD","LU1066051498.USD","IE000M9KFDE8.USD","LU0122379950.USD","LU1066053197.SGD","BK4568","LU0456855351.SGD","BK4550","BK4533","LU0306807586.USD","LU0170899867.USD","BK4581","BK4585","BK4588","BK4007","LU0225771236.USD","LU1023059063.AUD","BK4534","SGXZ57979304.SGD","LU0225284248.USD","LU0321505868.SGD","LU1883839398.USD","SG9999013999.USD","LU1057294990.SGD","IE00B19Z3B42.SGD","LU0306806265.USD","IE00BLSP4452.SGD","PFE","SG9999003800.SGD","IE00B19Z3581.USD","IE00BBT3K403.USD","SG9999002232.USD","BK4599","LU1894683264.USD","LU1894683348.USD","LU0058720904.USD","IE0002270589.USD","SG9999001176.SGD","LU0321505439.SGD","SG9999002224.SGD","LU0289739699.SGD"],"gpt_icon":1},{"id":"2534115173","title":"Corvus Pharmaceuticals, Inc.盘中异动 股价大涨5.00%报3.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2534115173","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534115173?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 00:00","pubTimestamp":1746720054,"startTime":"0","endTime":"0","summary":"北京时间2025年05月09日00时00分，Corvus Pharmaceuticals, Inc.股票出现波动，股价快速上涨5.00%。Corvus Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为2.46%。Corvus Pharmaceuticals, Inc.公司简介：Corvus Pharmaceuticals Inc 是一家临床阶段的生物制药公司，致力于开发针对免疫系统关键细胞元素的药物和抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509000054975367b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509000054975367b1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","CRVS","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":187,"code":"91000000","status":"200"}]}}